IL-10 Antikörper (PerCP-Cy5.5)
-
- Target Alle IL-10 (IL10) Antikörper anzeigen
- IL-10 (IL10) (Interleukin 10 (IL10))
-
Reaktivität
- Human
-
Wirt
- Ratte
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser IL-10 Antikörper ist konjugiert mit PerCP-Cy5.5
-
Applikation
- Flow Cytometry (FACS)
- Kreuzreaktivität
- Pavian, Rhesusaffen, Cynomolgus
- Aufreinigung
- The antibody was purified by affinity chromatography and conjugated with PerCP/Cy5.5 under optimal conditions. The solution is free of unconjugated PerCP/Cy5.5 and unconjugated antibody.
- Klon
- JES3-9D7
- Isotyp
- IgG1 kappa
- Top Product
- Discover our top product IL10 Primärantikörper
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Handhabung
- Protect from prolonged exposure to light. Do not freeze.
- Lagerung
- 4 °C
- Informationen zur Lagerung
- The antibody solution should be stored undiluted between 2°C and 8°C.
-
- Target
- IL-10 (IL10) (Interleukin 10 (IL10))
- Andere Bezeichnung
- IL-10 (IL10 Produkte)
- Hintergrund
- IL-10 was originally described as Cytokine Synthesis Inhibitory Factor (CSIF) by virtue of its ability to inhibit cytokine production by Th1 clones. IL-10 shares over 80 % sequence homology with the Epstein-Barr virus protein BCRFI. The biological activities of IL-10 include inhibition of macrophage-mediated cytokine synthesis, suppression of the delayed type hypersensitivity response, and stimulation of the Th2 cell response, which results in elevated antibody production.
- Pathways
- Cellular Response to Molecule of Bacterial Origin, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Maintenance of Protein Location, Cancer Immune Checkpoints
-